CASP1 and myelodysplastic syndrome: Ibrutinib, a BTK inhibitor that prevents the formation of ASC specks and Caspase 1 activation is used in combination with lenalidomide and 5′-Azacytidine is under phase 1 clinical trials for MDS (NCT03359460 and NCT02553941) [66, 69].